Albireo Pharma, Inc. (ALBO) stock price escalated 0.55% to finalize at $33.13 throughout previous buying and selling session. A total of 0.07 million shares exchanged at hands and its average trading volume is standing at 0.06 million shares. Important factors to focus when evaluating a stock’s present and future value are the 52 week price high and low levels. Shares of Albireo Pharma, Inc. (ALBO) are trading -16.90% downward from the 52-week high mark and 116.39% above from the fifty two-week low mark.
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, reported the first patient has been enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor being studied for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).
“A PFIC diagnosis for our children was shocking and devastating, and we quickly found out that current treatment options are inadequate,” stated Kristen and Michael Busby of New York, parents of two children with PFIC. “We applaud all research in this area, and it is great news to see a clinical trial as an option for children with PFIC.”
Relative strength index (RSI-14) for Albireo Pharma, Inc. (ALBO) is at 59.03. In phrases of Market analysis and buying and selling signals, RSI moving above the horizontal 30 reference standard is regarded as a bullish indicator, at the same time as the RSI transferring under the horizontal 70 reference standard is visible to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely moves underneath 30 notify oversold conditions.
King’s College London and principal investigator of the study, Professor Richard Thompson, said that they are very excited to have the first patient enrolled into the PEDFIC-1 pivotal study to determine the potential of A4250, with the goal of providing new options to patients with this debilitating disease furthermore he added “The results of the Phase 2 trial, where A4250 reduced serum bile acids and decreased pruritus in most patients, while showing a favourable overall tolerability profile, gives us optimism and confidence that A4250 could be an excellent medical treatment option.”
The Phase 3 program includes a single randomized, double-blind, placebo-controlled clinical trial designed to evaluate A4250 in 60 patients, ages 6 months to 18 years, with PFIC (subtype 1 or 2), elevated serum bile acid (sBA) levels and pruritus, and an open-label extension study to assess long-term safety and durability of response. Patients in the double-blind trial will receive a 40 or 120 μg/kg oral dose of A4250 or placebo once daily for 24 weeks. The primary endpoint for the US Food and Drug Administration (FDA) evaluation will be an assessment of change in pruritus, and the primary endpoint for the European Medicines Agency (EMA) evaluation will be sBA responder rate.